Objective: To investigate the predictive value of serum C3 and C4 complement component levels in relation to pregnancy outcome in patients with antiphospholipid syndrome (APS).
Materials and methods: A prospective study of 47 pregnancies associated with APS was performed. Pregnancy outcome was analyzed in terms of: fetal loss, preterm delivery (≤34 gestational weeks), fetal intrauterine growth restriction (IUGR), birth weight <2500 g and preeclampsia. Week at delivery, neonatal birth weight and neonatal birth weight percentile were also investigated. Hypocomplementemia, positivity for anti-dsDNA and triple positivity for antiphospholipid antibodies (aPL) were related to pregnancy outcome.
Results: Forty-three pregnancies ended in live births with a fetal loss rate of 8.5%. Fetal death, preterm delivery and birth weight <2500 g were associated with hypocomplementemia (p = 0.019, p = 0.0002, p < 0.0001 respectively). Lower neonatal birth weight, lower neonatal birth weight percentile and lower week at delivery were associated with hypocomplementemia (p < 0.0001, p = 0.0003, p < 0.0001 respectively) and with triple aPL positivity (p = 0.008, p = 0.014, p = 0.03 respectively). A poor pregnancy outcome was confirmed among primary APS (PAPS) pregnancies with hypocomplementemia. Multivariate analysis confirmed that hypocomplementemia was an independent predictor of lower neonatal birth weight (p = 0.0001) and lower week at delivery (p = 0.002).
Conclusion: Hypocomplementemia could be considered a novel prognostic factor for pregnancy outcome in APS patients.
HolersVMGirardiGMoL. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med2002; 195: 211–220.
2.
PierangeliSSGirardiGVega-OstertagM. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum2005; 52: 2120–2124.
3.
De Carolis S, Botta A, Santucci S, et al. Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin Rev Allergy Immunol 2010; 38: 116–124.
4.
MiyakisSLockshinMDAtsumiT. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006; 4: 295–306.
5.
TincaniABranchWLevyRA. Treatment of pregnant patients with antiphospholipid syndrome. Lupus2003; 12: 524–529.
6.
De CarolisSSantucciSBottaA. False-positive IgM for CMV in pregnant women with autoimmune disease: a novel prognostic factor for poor pregnancy outcome. Lupus2010; 19: 844–849.
7.
De CarolisSBottaAGarofaloS. Uterine artery velocity waveforms as predictors of pregnancy outcome in patients with antiphospholipid syndrome: a review. Ann NY Acad Sci2007; 1108: 530–539.
8.
ClowseMEMagderLSPetriM. The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol2011; 38: 1012–1016.
9.
RuffattiACalligaroAHoxhaA. Laboratory and clinical features of pregnant women with antiphospholipid syndrome and neonatal outcome. Arthritis Care Res2010 Mar; 62: 302–307.
10.
Venkat-RamanNBackosMTeohTG. Uterine artery Doppler in predicting pregnancy outcome in women with antiphospholipid syndrome. Obstet Gynecol2001; 98: 235–242.
11.
Le Thi HuongDWechslerBVauthier-BrouzesD. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford)2006; 45: 332–338.
